Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of ONC201 in Recurrent or Metastatic Type II Endometrial Cancer

NCT03485729 is registered in ClinicalTrials.gov with Jazz Pharmaceuticals as lead sponsor.

NCT NCT03485729
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03485729 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of ONC201 in Recurrent or Metastatic Type II Endometrial Cancer
Lead sponsor
Jazz Pharmaceuticals
Phase
Phase 2
Overall status
Terminated
Start date
March 21, 2018
Completion date
January 19, 2023
Enrollment
27 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer recurrent